Lin Shen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2971900/publications.pdf

Version: 2024-02-01

95	11,142	117625	30922
papers	citations	34	102
		h-index	g-index

113	113	113	12507
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	PTCH1 mutation promotes antitumor immunity and the response to immune checkpoint inhibitors in colorectal cancer patients. Cancer Immunology, Immunotherapy, 2022, 71, 111-120.	4.2	11
2	Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer. Cancer Biology and Medicine, 2022, 19, 1139-1149.	3.0	4
3	Characteristics and Prognosis of Acquired Resistance to Immune Checkpoint Inhibitors in Gastrointestinal Cancer. JAMA Network Open, 2022, 5, e224637.	5.9	6
4	Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR/MSI-H gastric adenocarcinoma. BMC Medicine, 2022, 20, 133.	5.5	27
5	Early change in peripheral CD4⁺ T cells associated with clinical outcomes of immunotherapy in gastrointestinal cancer. Immunotherapy, 2021, 13, 55-66.	2.0	15
6	A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer. Npj Precision Oncology, 2021, 5, 36.	5.4	20
7	Genetic differences between lung metastases and liver metastases from left-sided microsatellite stable colorectal cancer: next generation sequencing and clinical implications. Annals of Translational Medicine, 2021, 9, 967-967.	1.7	7
8	The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Communications, 2021, 41, 747-795.	9.2	323
9	Treatment Patterns and Outcomes in Chinese Patients with Gastric Cancer by <scp>HER2</scp> Status: A Noninterventional Registry Study (<scp>EVIDENCE</scp>). Oncologist, 2021, 26, e1567-e1580.	3.7	15
10	Preclinical model-based evaluation of Imatinib resistance induced by mutations and its overcoming strategies in gastrointestinal stromal tumor (GIST).. American Journal of Translational Research (discontinued), 2021, 13, 13608-13624.	0.0	1
11	Epigenetic therapy inhibits metastases by disrupting premetastatic niches. Nature, 2020, 579, 284-290.	27.8	213
12	Positive Status of Epstein-Barr Virus as a Biomarker for Gastric Cancer Immunotherapy: A Prospective Observational Study. Journal of Immunotherapy, 2020, 43, 139-144.	2.4	61
13	Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2â€targeted therapies. Clinical and Translational Medicine, 2020, 10, e254.	4.0	23
14	Conditionally reprogrammed colorectal cancer cells combined with mouse avatars identify synergy between EGFR and MEK or CDK4/6 inhibitors. American Journal of Cancer Research, 2020, 10, 249-262.	1.4	7
15	Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2â€positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial. Cancer Communications, 2019, 39, 1-10.	9.2	19
16	Chromosomal instability of circulating tumor DNA reflect therapeutic responses in advanced gastric cancer. Cell Death and Disease, 2019, 10, 697.	6.3	18
17	Clinicopathologic Characteristics of HER2-positive Metastatic Colorectal Cancer and Detection of HER2 in Plasma Circulating Tumor DNA. Clinical Colorectal Cancer, 2019, 18, 175-182.	2.3	11
18	The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Communications, 2019, 39, 1-31.	9.2	418

#	Article	IF	Citations
19	Prognostic Value of Inflammation-Based Markers in Advanced or Metastatic Neuroendocrine Tumours. Current Oncology, 2019, 26, 4135.	2.2	14
20	EPHA2 blockade reverses acquired resistance to afatinib induced by EPHA2â€mediated MAPK pathway activation in gastric cancer cells and avatar mice. International Journal of Cancer, 2019, 145, 2440-2449.	5.1	20
21	Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019) Tj ETQq1 1 0.784314 rgBT /Overlock	17.0	69
22	Targeting autophagy potentiates antitumor activity of Met-TKIs against Met-amplified gastric cancer. Cell Death and Disease, 2019, 10, 139.	6.3	16
23	A proteomic landscape of diffuse-type gastric cancer. Nature Communications, 2018, 9, 1012.	12.8	175
24	Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway. Cell Death and Disease, 2018, 9, 123.	6.3	76
25	Survival Benefit of Palliative Local Treatments and Efficacy of Different Pharmacotherapies in Colorectal Cancer With Lung Metastasis: Results From a Large Retrospective Study. Clinical Colorectal Cancer, 2018, 17, e233-e255.	2.3	26
26	Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer. Journal of Hematology and Oncology, 2018, 11, 20.	17.0	32
27	Noninvasive Detection of HER2 Expression in Gastric Cancer by ⁶⁴Cu-NOTA-Trastuzumab in PDX Mouse Model and in Patients. Molecular Pharmaceutics, 2018, 15, 5174-5182.	4.6	18
28	Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncology, The, 2018, 19, 1372-1384.	10.7	319
29	Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint. Journal of Experimental and Clinical Cancer Research, 2018, 37, 129.	8.6	37
30	Wee1 Inhibitor AZD1775 Combined with Cisplatin Potentiates Anticancer Activity against Gastric Cancer by Increasing DNA Damage and Cell Apoptosis. BioMed Research International, 2018, 2018, 1-10.	1.9	18
31	Establishment and genomic characterizations of patient-derived esophageal squamous cell carcinoma xenograft models using biopsies for treatment optimization. Journal of Translational Medicine, 2018, 16, 15.	4.4	29
32	HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer. European Journal of Cancer, 2018, 88, 92-100.	2.8	64
33	Circulating tumor <scp>DNA</scp> functions as an alternative for tissue to overcome tumor heterogeneity in advanced gastric cancer. Cancer Science, 2017, 108, 1881-1887.	3.9	51
34	Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis. BMC Cancer, 2017, 17, 437.	2.6	21
35	CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest. Journal of Translational Medicine, 2017, 15, 127.	4.4	45
36	Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. Journal of Hematology and Oncology, 2017, 10, 22.	17.0	50

#	Article	IF	Citations
37	Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study. Chinese Journal of Cancer, 2017, 36, 81.	4.9	13
38	Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial. Chinese Journal of Cancer, 2017, 36, 97.	4.9	28
39	Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2017, 29, 281-293.	2.2	117
40	miR-215 promotes malignant progression of gastric cancer by targeting RUNX1. Oncotarget, 2016, 7, 4817-4828.	1.8	54
41	Clinicopathologic and Molecular Features of Colorectal Adenocarcinoma with Signet-Ring Cell Component. PLoS ONE, 2016, 11, e0156659.	2.5	25
42	Risk prediction for early-onset gastric carcinoma: a case-control study of polygenic gastric cancer in Han Chinese with hereditary background. Oncotarget, 2016, 7, 33608-33615.	1.8	16
43	Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor. Cancer Research and Treatment, 2016, 48, 1155-1166.	3.0	142
44	Famitinib exerted powerful antitumor activity in human gastric cancer cells and xenografts. Oncology Letters, 2016, 12, 1763-1768.	1.8	9
45	Pretreatment lymphopenia is an easily detectable predictive and prognostic marker in patients with metastatic esophagus squamous cell carcinoma receiving firstâ€line chemotherapy. Cancer Medicine, 2016, 5, 778-786.	2.8	30
46	PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer. Human Pathology, 2016, 55, 182-189.	2.0	58
47	Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial. BMC Cancer, 2016, 16, 68.	2.6	82
48	Expert consensus on maintenance treatment for metastatic colorectal cancer in China. Chinese Journal of Cancer, 2016, 35, 13.	4.9	14
49	Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer. British Journal of Cancer, 2016, 114, 138-145.	6.4	81
50	Reply to the letter by Takeshi Yamada et al. concerning â€œIs serum HER2 ECD a predictive biomarker for response to trastuzumab in advanced gastric cancer?â€• Journal of Gastroenterology, 2016, 51, 508-508.	5.1	0
51	Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer. Gastric Cancer, 2016, 19, 234-244.	5.3	90
52	Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study. Oncotarget, 2016, 7, 50656-50665.	1.8	39
53	Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors. Oncotarget, 2016, 7, 30241-30249.	1.8	11
54	Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA in situ hybridization and its clinical significance. Oncotarget, 2016, 7, 39671-39679.	1.8	37

#	Article	IF	Citations
55	Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer. BMC Cancer, 2015, 15, 894.	2.6	27
56	Expression and clinical significance of c-Met in advanced esophageal squamous cell carcinoma. BMC Cancer, 2015, 15, 6.	2.6	27
57	Integrating biomarkers in colorectal cancer trials in the West and China. Nature Reviews Clinical Oncology, 2015, 12, 553-560.	27.6	11
58	Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy. Journal of Gastroenterology, 2015, 50, 955-961.	5.1	11
59	Establishment and characterization of patient-derived tumor xenograft using gastroscopic biopsies in gastric cancer. Scientific Reports, 2015, 5, 8542.	3.3	66
60	PI3K/AKT/mTOR pathway is activated after imatinib secondary resistance in gastrointestinal stromal tumors (GISTs). Medical Oncology, 2015, 32, 111.	2.5	36
61	Tumor MET Expression and Gene Amplification in Chinese Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer. Molecular Cancer Therapeutics, 2015, 14, 2634-2641.	4.1	20
62	Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer, 2015, 18, 168-176.	5.3	209
63	Prognostic Significance of MET Amplification and Expression in Gastric Cancer: A Systematic Review with Meta-Analysis. PLoS ONE, 2014, 9, e84502.	2.5	80
64	Change of Body Weight and Macrophage Inhibitory Cytokine-1 during Chemotherapy in Advanced Gastric Cancer: What Is Their Clinical Significance?. PLoS ONE, 2014, 9, e88553.	2.5	37
65	Predictive biomarkers for the efficacy of cetuximab combined with cisplatin and capecitabine in advanced gastric or esophagogastric junction adenocarcinoma: a prospective multicenter phase 2 trial. Medical Oncology, 2014, 31, 226.	2.5	15
66	The Multicenter, Phase II Prospective Study of Paclitaxel Plus Capecitabine as First-Line Chemotherapy in Advanced Gastric Carcinoma. Oncologist, 2014, 19, 173-174.	3.7	9
67	Serum HER2 extracellular domain as a potential alternative for tissue HER2 status in metastatic gastric cancer patients. Biomarkers in Medicine, 2014, 8, 663-670.	1.4	14
68	Axitinib alone or in combination with chemotherapeutic drugs exerts potent antitumor activity against human gastric cancer cells in vitro and in vivo. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1575-1583.	2.5	13
69	Combination of microtubule associated protein-tau and Î²-tubulin III predicts chemosensitivity of paclitaxel in patients with advanced gastric cancer. European Journal of Cancer, 2014, 50, 2328-2335.	2.8	24
70	Association between CHFR methylation and chemosensitivity of paclitaxel in advanced gastric cancer. Medical Oncology, 2014, 31, 907.	2.5	8
71	p16 Methylation is associated with chemosensitivity to fluorouracil in patients with advanced gastric cancer. Medical Oncology, 2014, 31, 988.	2.5	16
72	Clinical significance of phenotyping and karyotyping of circulating tumor cells in patients with advanced gastric cancer. Oncotarget, 2014, 5, 6594-6602.	1.8	69

#	Article	IF	Citations
73	Neutrophil Count and the Inflammation-based Glasgow Prognostic Score Predict Survival in Patients with Advanced Gastric Cancer Receiving First-line Chemotherapy. Asian Pacific Journal of Cancer Prevention, 2014, 15, 945-950.	1.2	79
74	Associations between UGT1A1*6/*28 polymorphisms and irinotecan-induced severe toxicity in Chinese gastric or esophageal cancer patients. Medical Oncology, 2013, 30, 630.	2.5	16
75	UGT1A1*6/*28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients. Medical Oncology, 2013, 30, 604.	2.5	33
76	Association between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: a systematic review and meta-analysis. Cancer Chemotherapy and Pharmacology, 2013, 72, 305-314.	2.3	29
77	Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study. Journal of Clinical Oncology, 2013, 31, 3935-3943.	1.6	411
78	Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncology, The, 2013, 14, e535-e547.	10.7	418
79	High level of serum AMBP is associated with poor response to paclitaxelâ€“capecitabine chemotherapy in advanced gastric cancer patients. Medical Oncology, 2013, 30, 748.	2.5	23
80	MicroRNA-215 inhibits relapse of colorectal cancer patients following radical surgery. Medical Oncology, 2013, 30, 549.	2.5	35
81	Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors. Medical Oncology, 2013, 30, 522.	2.5	27
82	Synergistic inhibitory effect of wogonin and low-dose paclitaxel on gastric cancer cells and tumor xenografts. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2013, 25, 505-13.	2.2	11
83	The assessment of clinicopathological features, therapy pattern and survival benefit of 162 gastric cancers with liver metastases. Hepato-Gastroenterology, 2013, 60, 628-32.	0.5	2
84	Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors. Future Oncology, 2012, 8, 617-624.	2.4	25
85	Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine. Medical Oncology, 2012, 29, 3029-3034.	2.5	19
86	C-KIT mutations were closely associated with the response to Imatinib in Chinese advanced gastrointestinal stromal tumor patients. Medical Oncology, 2012, 29, 3039-3045.	2.5	18
87	Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. Chinese Journal of Cancer, 2011, 30, 682-689.	4.9	103
88	Wild-type KRAS and BRAF could predict response to Cetuximab in Chinese colorectal cancer patients. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2011, 23, 271-275.	2.2	13
89	Expressions of thymidylate synthase, thymidine phosphorylase, class III Î²-tubulin, and excision repair cross-complementing group 1 predict response in advanced gastric cancer patients receiving capecitabine plus paclitaxel or cisplatin. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2011, 23, 288-294.	2.2	18
90	Thymidine Phosphorylase/Î²-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel. BMC Cancer, 2011, 11, 177.	2.6	25

#	Article	IF	Citations
91	Capecitabine maintenance therapy after first-line chemotherapy in patients with metastatic colorectal cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2010, 22, 181-185.	2.2	5
92	Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, The, 2010, 376, 687-697.	13.7	5,899
93	Impact ofKRASmutation and PTEN expression on cetuximab-treated colorectal cancer. World Journal of Gastroenterology, 2010, 16, 5881.	3.3	19
94	Retrospective study of cetuximab in combination with chemotherapy for patients with colorectal cancer. Chinese-German Journal of Clinical Oncology, 2008, 7, 400-403.	0.1	1
95	A Phase II Trial of Paclitaxel and Cisplatin in Patients With Advanced Squamous-Cell Carcinoma of the Esophagus. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 29-33.	1.3	49